- Trial phase
- Phase 1
- Time to market
- Likely several years away, if successful. The program is still in Phase 1 with no Phase 2/3 design announced.
- Why 4/10
- RP-A601 is in Phase 1 with no scheduled pivotal readout or PDUFA date in the next ~12 months. The next catalyst is a regulatory update on Phase 2 path, which is not a hard binary event. The drug is one of three prioritized cardiovascular gene therapy programs at Rocket, alongside RP-A501 (Danon disease, pivotal Phase 2 data expected early 2027) and RP-A701 (BAG3-DCM).
RP-A601 is an early-stage gene therapy program with encouraging but very preliminary Phase 1 data. The next meaningful catalyst is likely a regulatory update on Phase 2 trial design, which Rocket has not yet scheduled. Investors should watch for updates in Rocket's quarterly earnings calls and whether the company provides a timeline for advancing RP-A601 into a Phase 2/3 study. The stock's primary near-term value driver is RP-A501 for Danon disease, with pivotal Phase 2 data expected in early 2027.
Price Chart
Executive Summary
RP-A601 is an AAV9-based gene therapy from Rocket Pharmaceuticals (RCKT) for PKP2-arrhythmogenic cardiomyopathy (PKP2-ACM), a rare genetic heart disease affecting roughly 50,000 people in the US and EU. It is in Phase 1 clinical development with preliminary data from May 2025 showing early safety and signals of efficacy. The FDA has granted it Fast Track, Orphan Drug, and RMAT designations. However, RP-A601 is still early-stage and is one of three prioritized cardiovascular gene therapy programs at Rocket. The stock trades near $2.31, down sharply from its 52-week high of $5.45, reflecting the clinical hold and death that occurred in the RP-A501 Danon disease program in May 2025 (a separate program), which severely impacted investor sentiment across the company. RP-A601 faces competition from Tenaya Therapeutics' TN-401, a similar PKP2 gene therapy in Phase 1b/2.
How It Works
RP-A601 is an experimental gene therapy that uses a harmless virus (AAV9) to deliver a working copy of the PKP2 gene directly into heart muscle cells. PKP2 mutations cause a genetic heart condition where the heart muscle is replaced by fatty or fibrous tissue, leading to dangerous heart rhythms and sudden cardiac death. By restoring the missing protein, the therapy aims to stabilize heart cells and prevent life-threatening arrhythmias.
Trial Status
RP-A601 is in an ongoing Phase 1 dose-escalation clinical trial for PKP2-arrhythmogenic cardiomyopathy (PKP2-ACM). Preliminary data were presented as a late-breaking oral presentation at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) in May 2025. The data showed early signs of safety and efficacy, including reductions in ventricular arrhythmia burden and improvements in quality-of-life measures. The company has received FDA Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy (RMAT) designations for RP-A601, as well as Orphan Medicinal Product designation from the European Commission. Rocket is engaging with the FDA on the path forward, but no Phase 2/3 trial design has been announced as of the Q3 2026 earnings report (November 12, 2026).
The Two-Sided Case
Upcoming Catalysts
- Regulatory update on Phase 2 path for RP-A601 (timing not yet announced)
- Rocket Q4 2026 earnings and pipeline update (expected early 2027)
- Pivotal Phase 2 data for RP-A501 in Danon disease (expected early 2027), which could derisk the broader AAV9 platform
Source Filing
The SecBot filing or press-release report that triggered this drug report:
ROCKET PHARMACEUTICALS, INC. CLUSTER RCKT ·Originating report